"Well," Archangel said over her shoulder, "they started out developing biomed facilities, but after 2052 turned strictly R&D. They haven’t come out with any major commercial products yet, but basically they specialize in wetware—transplants, gene therapy, tissue tech, and regeneration. Repairing cellular damage. Mostly muscle tissue, tendons. Ultimately, they’d like to induce damaged tissue to renew itself organically." Archangel turned back to the screen. "But no one knows what they’ve accomplished. They’ve operated solely in the Tir, never gone beyond its borders."